<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409942</url>
  </required_header>
  <id_info>
    <org_study_id>N/GF-TORAFIC-06</org_study_id>
    <secondary_id>EudraCT number 2006-001446-14</secondary_id>
    <nct_id>NCT00409942</nct_id>
  </id_info>
  <brief_title>Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.</brief_title>
  <acronym>TORAFIC</acronym>
  <official_title>Prospective, Randomised, Open, Blinded-endpoint Study of Torasemide Prolonged Release vs Furosemide to Evaluate the Efficacy on Myocardial Fibrosis in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferrer Internacional S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferrer Internacional S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Torasemide is a loop diuretic (pyridine-sulfonylurea)with a wide experience in the treatment
      of oedema associated to heart failure, kidney or liver disease and either in the treatment of
      arterial hypertension (alone or combined with other anti-hypertensive drugs). It has been
      developed a new formulation of Torasemide (Torasemide prolonged release).

      The aim of this trial is to study the effects of Torasemide prolonged released in comparison
      with furosemide, in the reduction of myocardial fibrosis in patients with chronic heart
      failure (Class II-IV of the New York Heart Association Classification.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial fibrosis reduction:measure of Serum carboxy-terminal peptide of procollagen type 1.</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement (New York Heart Association classification, signs and symptoms of heart failure)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-proBNP (Brain Natriuretic Peptide)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations, home care due to cardiovascular causes related to heart failure</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Minnesota Test)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Torasemide prolonged released</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Furosemide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torasemide Prolonged Release</intervention_name>
    <description>Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Torasemide Prolonged release:Sutril neo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Furosemide: Seguril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged over 18

          -  Patients with chronic heart failure class II-IV (NYHA)due to arterial hypertension

          -  Patients clinically stable who required diuretic treatment

          -  Patients with left ventricular hypertrophy diagnosed by echocardiogram

          -  Patients without ischaemic cardiopathy or non recent disease

          -  Signed Informed Consent

        Exclusion Criteria:

          -  Heart Failure due to aortic stenosis or hypertrophic myocardiopathy

          -  Recent coronary syndrome (less than 3 months)

          -  Recent myocardial infarction (less than 6 months)

          -  Unstable angor pectoris

          -  Severe cardiac arrhythmia

          -  Pregnancy or breastfeeding

          -  Aldosterone antagonists (last 6 months)

          -  Current loop diuretic treatment over study doses (torasemide &gt; 10mg/day furosemide &gt;
             40 mg/day)

          -  known hypersensitivity to study drugs

          -  Liver disease (SGPT or AST &gt; twice upper normal limt)

          -  Renal impairment (Serum creatinine &gt; 2,5mg/dl)

          -  Insulin-dependent diabetes

          -  Patient included in another simultaneous study

          -  Lactose intolerance

          -  Lithium Concomitant treatment

          -  Chronic treatment with NSAIDs

          -  Concomitant treatment with aminoglycoside antibiotics,etacrynic acid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Coca, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Anguita, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Reina Sofia - Córdoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo De Teresa, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clinico - Málaga</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfonso Castro Beiras, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Juan Canalejo - Coruña</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Díez</last_name>
    <role>Study Director</role>
    <affiliation>Centro Investigación Médica Aplicada (CIMA) - Pamplona (Navarra)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canet de Mar, Primary Care Centre</name>
      <address>
        <city>Canet de Mar</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centelles - Primar Care Centre</name>
      <address>
        <city>Centellas</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Maresme - Primary Care Centre</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remei, Primary care centre</name>
      <address>
        <city>Vic</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Begonte - Primary Care Centre</name>
      <address>
        <city>Begonte</city>
        <state>Lugo</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinico Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <state>Malaga</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donostia Hospital</name>
      <address>
        <city>Donostia</city>
        <state>San Sebastián</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcover - primary care centre</name>
      <address>
        <city>Alcover</city>
        <state>Tarragona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinc Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valle Hebrón Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reina Sofia Hospital</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josep Trueta Hospital</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jorge Hospital</name>
      <address>
        <city>Huesca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Juan Canalejo</name>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gregorio Marañón Hospital</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinico Universitario Hospital</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinico Universitario</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Querejeta R, López B, González A, Sánchez E, Larman M, Martínez Ubago JL, Díez J. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004 Sep 7;110(10):1263-8. Epub 2004 Aug 16.</citation>
    <PMID>15313958</PMID>
  </reference>
  <reference>
    <citation>González A, López B, Díez J. New directions in the assessment and treatment of hypertensive heart disease. Curr Opin Nephrol Hypertens. 2005 Sep;14(5):428-34. Review.</citation>
    <PMID>16046900</PMID>
  </reference>
  <reference>
    <citation>López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004 Jun 2;43(11):2028-35.</citation>
    <PMID>15172408</PMID>
  </reference>
  <reference>
    <citation>López B, González A, Querejeta R, Díez J. The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens. 2005 Aug;23(8):1445-51. Review.</citation>
    <PMID>16003166</PMID>
  </reference>
  <reference>
    <citation>López B, González A, Beaumont J, Querejeta R, Larman M, Díez J. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007 Aug 28;50(9):859-67. Epub 2007 Aug 13.</citation>
    <PMID>17719472</PMID>
  </reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2006</study_first_submitted>
  <study_first_submitted_qc>December 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2006</study_first_posted>
  <last_update_submitted>July 14, 2009</last_update_submitted>
  <last_update_submitted_qc>July 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Savion Gropper</name_title>
    <organization>ferrer</organization>
  </responsible_party>
  <keyword>Chronic heart failure</keyword>
  <keyword>Torasemide prolonged release</keyword>
  <keyword>Myocardial fibrosis</keyword>
  <keyword>Loop diuretics</keyword>
  <keyword>Peptide of procollagen type 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Torsemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

